文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Kabasura Kudineer 降低无症状 COVID-19 病毒载量的随机对照探索性试验

Kabasura Kudineer (KSK), a poly-herbal Siddha medicine, reduced SARS-CoV-2 viral load in asymptomatic COVID-19 individuals as compared to vitamin C and zinc supplementation: findings from a prospective, exploratory, open-labeled, comparative, randomized controlled trial, Tamil Nadu, India.
PubMed 文献 · Trials · 2021-09-15

该研究在印度金奈对无症状 COVID-19 患者开展前瞻性、单中心、开放标签随机对照试验,比较 KSK 与维生素 C 联合锌补充对病毒载量的影响,发现 KSK 组第 7 天 CT 值显著下降且无进展为症状性病例。

要点

  • KSK 组第 7 天病毒载量(CT 值)显著下降,较对照组更明显。
  • 两组均无进展为症状性状态,生化指标无显著差异。
  • KSK 组未观察到不良反应或 Siddha 临床评估变化。

核心结论

  • KSK 显著降低无症状 COVID-19 病例的 SARS-CoV-2 病毒载量,且未记录不良反应。

研究设计与样本

  • 前瞻性、单中心、开放标签、比较性随机对照试验,在印度金奈 COVID 护理中心开展。
  • 纳入 18 至 55 岁、RT-PCR 确诊、无症状且无合并症的 COVID-19 患者,按 1:1 随机分组。
  • KSK 组给予 KSK 60 mL 每日两次共 7 天;对照组给予维生素 C 60,000 IU 每日晨服加锌 100 mg 每日晚服共 7 天。

主要发现

  • KSK 组第 7 天 CT 值(RdRp:95%CI=1.89 至 5.74)显著下降,对照组亦下降但 KSK 组更明显。
  • 两组均无患者进展为症状性状态。
  • 两组生化参数无显著差异。
  • 两组 Siddha 临床评估及不良事件均无变化。

关键数值与推荐

  • 主要结局包括 SARS-CoV-2 载量(RT-PCR 的 CT 值)下降、无症状向症状性进展的预防及免疫标志物变化。
  • 免疫标志物包括 IL-6、IL-10、IL-2、IFNγ 和 TNFα。
  • 统计分析采用配对 t 检验。

临床怎么用

  • KSK 或可作为无症状 COVID-19 病例降低病毒载量的策略之一。
  • 需更大规模多中心试验进一步验证当前发现。

局限性

  • 单中心、开放标签、探索性设计。
  • 样本量未在摘要中报告。
  • 需更大规模多中心试验强化证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite several ongoing efforts in biomedicine and traditional medicine, there are no drugs or vaccines for coronavirus disease 2019 (COVID-19) as of May 2020; Kabasura Kudineer (KSK), a polyherbal formulation from India's Siddha system of medicine, has been traditionally used for clinical presentations similar to that of COVID-19. We explored the efficacy of KSK in reducing viral load and preventing the disease progression in asymptomatic, COVID-19 cases. METHODS: A prospective, single-center, open-labeled, randomized, controlled trial was conducted in a COVID Care Centre in Chennai, India. We recruited reverse-transcription polymerase chain reaction (RT-PCR)-confirmed COVID-19 of 18 to 55 years of age, without clinical symptoms and co-morbidities. They were randomized (1:1 ratio) to KSK (60 mL twice daily for 7 days) or standard of care (7 days supplementation of vitamin C 60,000 IU morning daily and zinc 100 mg evening daily) groups. The primary outcomes were reduction in the SARS-CoV-2 load [as measured by cyclic threshold (CT) value of RT-PCR], prevention of progression of asymptomatic to symptomatic state, and changes in the immunity markers including interleukins (IL-6, IL-10, IL-2), interferon gamma (IFNγ), and tumor necrosis factor (TNF α). Siddha clinical assessment and the occurrence of adverse effects were documented as secondary outcomes. Paired t-test was used in statistical analysis. RESULTS: Viral load in terms of the CT value (RdRp: 95% CI = 1.89 to 5.74) declined significantly on the seventh day in the KSK group and that of the control group, more pronounced in the study group. None progressed to the symptomatic state. There was no significant difference in the biochemical parameters. We did not observe any changes in the Siddha-based clinical examination and adverse events in both groups. CONCLUSION: KSK significantly reduced SARS-CoV-2 viral load among asymptomatic COVID-19 cases and did not record any adverse effect, indicating the use of KSK in the strategy against COVID-19. Larger, multi-centric trials can strengthen the current findings. TRIAL REGISTRATION: Clinical Trial Registry of India CTRI2020/05/025215 . Registered on 16 May 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Natarajan S, Anbarasi C, Sathiyarajeswaran P, et al. Kabasura Kudineer (KSK), a poly-herbal Siddha medicine, reduced SARS-CoV-2 viral load in asymptomatic COVID-19 individuals as compared to vitamin C and zinc supplementation: findings from a prospective, exploratory, open-labeled, comparative, randomized controlled trial, Tamil Nadu, India. Trials. 2021. PMID: 34526104. doi:10.1186/s13063-021-05583-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。